BioCryst is acquiring Astria Therapeutics for ~$700M, aiming to bolster its hereditary angioedema portfolio with navenibart. The deal targets market leader Takhzyro by offering navenibart's less ...

BioCryst Pharmaceuticals has seen its Fair Value Estimate rise from $16.73 to $18.50, signaling a more optimistic view of the company’s intrinsic worth. At the same time, the Discount Rate has inched ...

Investing.com - Oppenheimer downgraded Astria Therapeutics (NASDAQ:ATXS) from Outperform to Perform following the company’s acquisition agreement with BioCryst Pharmaceuticals . The stock, which has ...

Oct 14 (Reuters) - BioCryst Pharmaceuticals (BCRX.O), opens new tab said on Tuesday it would buy Astria Therapeutics (ATXS.O), opens new tab in a cash-and-stock deal valued at about $700 million, ...

(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) on Tuesday said it has agreed to acquire Astria Therapeutics, Inc. (ATXS) for an enterprise value of about $700 million, to be paid in cash and stock.

Having already established a commercial infrastructure for its oral hereditary angioedema (HAE) drug Orladeyo and eager to pinpoint the source of its future growth, BioCryst Pharmaceuticals has struck ...

RESEARCH TRIANGLE PARK, N.C., & BOSTON--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that the companies have entered into ...

– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE portfolio – – Solidifies double digit growth trajectory for HAE ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that the companies have entered into a definitive agreement under which BioCryst has agreed ...

(Reuters) -BioCryst Pharmaceuticals said on Tuesday it would buy Astria Therapeutics in a cash-and-stock deal valued at about $700 million, as it looks to expand its portfolio of treatments for rare ...